RoosterBio, Inc.
RoosterBio, Inc. specializes in simplifying the use of adult human mesenchymal stem/stromal cells (hMSCs) to accelerate the commercialization of therapeutic technologies. The company provides high-quality, scalable solutions for cell therapy, gene therapy, exosomes, tissue engineering, and bioprocessing, enabling researchers and developers to bring innovative therapies to market more efficiently. RoosterBio is committed to making living cells more affordable and accessible, driving the transition of hMSCs from a scarce resource into an abundant one. Established in 2013, RoosterBio aims to fuel the rapid implementation of scalable advanced therapies, ensuring that safe and effective treatments are widely available globally.
RoosterBio, Inc.
5295 Westview Drive, Suite 275, Frederick, MD 21703
What We Do
Services to help build clinical phase appropriate cGMP processes for specific product needs.
Analytical services for human mesenchymal stem/stromal cells.
Analytical services for exosomes and extracellular vesicles.
Available in multiple tissue and donor sources, manufactured under strict guidelines with standardized processes.
Media solutions for hMSC expansion and exosome production, available in cGMP formats.
Produced from multiple human tissue sources using optimized production processes.
Services
Show More (2)Vaccines
Key People
Chief Executive Officer
Founder & Chief Product Officer
Vice President, Quality Assurance & Regulatory Affairs
Chief Business Officer
Chief Financial Officer
News & Updates
Upcoming webinar on December 5th at 11:00 AM (ET) discussing analytical methods for clinical preparation.
An article discussing the collaboration between Cytiva and RoosterBio to enhance exosome manufacturing.
An article exploring the use of targeted exosomes in immunotherapy.
An article highlighting the advancements in extracellular vesicle technology.
Awarded by the Maryland Tech Council in 2024.
Recognized by the Maryland Tech Council in 2023.